Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;7(2):67-71.
doi: 10.2174/157340311797484204.

Immunologic considerations in heart transplantation for congenital heart disease

Beth D Kaufman  1 , Robert E Shaddy
Affiliations
Review

Immunologic considerations in heart transplantation for congenital heart disease

Beth D Kaufman et al. Curr Cardiol Rev. 2011 May.

Abstract

Children and adults with congenital heart disease (CHD) can require interventions that result in immunologic alterations that are different than those seen in patients with cardiomyopathies. Patients with CHD can be exposed to heart surgeries, blood products, valved and non-valved allograft tissue, and mechanical circulatory support, all of which can alter the immunologic status of these patients. This change in immunologic status is most commonly manifested as the development of anti-human leukocyte antigen (HLA) antibodies. This review will delineate a) the causes of anti-HLA anti-body production (often referred to as allosensitization); b) preventive strategies for anti-HLA antibody production before transplantation; c) treatment strategies for those patients who develop anti-HLA antibodies before transplantation; d) consequences of HLA allosensitization after transplantation; and e) treatment of HLA allosensitization and antibody-mediated rejection after transplantation.

Keywords: Heart transplantation; allosensitization; management.; pediatric; rejection; therapy.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Kaplan–Meier survival curve with log–rank statistics for graft and patient survival. PRA, Panel-reactive antibody. (With permission, 37).
See this image and copyright information in PMC

References

    1. Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation. 1996;94:1063–7. - PubMed
    1. Smith JD, Ogino H, Hunt D, Laylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg. 1995;60:S127–30. - PubMed
    1. Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg. 2000;119:324–30. - PubMed
    1. Breinholt JP, 3rd, Hawkins JA, Lambert LM, Fuller TC, Profaizer T, Shaddy RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation. 2000;102:III179–82. - PubMed
    1. Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Prospective follow-up of panel reactive antibodies in children 5-Years following implantation of cryopresaerved allografts. The Journal of Heart and Lung Transplantation. 2004;23:S168.

Publication types

MeSH terms